Trial · NCT07482085
Efavirenz for the Treatment of Creutzfeldt-Jakob Disease
NCT07482085, Phase 3, Recruiting, Xuanwu Hospital, Beijing
3 sourcestrials-2026-11-12-0.5.0
Cite this record
ConductScience Library. Efavirenz for the Treatment of Creutzfeldt-Jakob Disease. Trials, record NCT07482085. Release trials-2026-11-12-0.5.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT07482085
On this page
Trial
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
- Title
- Efavirenz for the Treatment of Creutzfeldt-Jakob Disease
- NCT number
- NCT07482085
- Status
- Recruiting
- Phases
- Phase 3
- Enrollment
- 246 participants, estimated
- Lead sponsor
- Xuanwu Hospital, Beijing
- Conditions
- Creutzfeldt-Jakob Disease
- Interventions
- Efavirenz, Placebo
- First posted
- 2026-03-19
- Last updated
- 2026-09-03
Source ClinicalTrials.gov
Registered outcomes6
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | Median survival time | From randomization to death, assessed up to 36 months | The median number of days from randomization to death |
| Secondary | Time to Loss of Independent Feeding Ability | From randomization until the feeding item in the Barthel Index first reaches 0, assessed up to 36 months | Time from randomization to the first occurrence of loss of independent feeding ability, defined as the first time the feeding item in the Barthel Index drops to 0 (days) |
| Secondary | Time to Loss of Bowel and Bladder Control | From randomization until both bowel and bladder control items in the Barthel Index first reach 0, assessed up to 36 months | Time from randomization to the first occurrence of loss of bowel and bladder control, defined as the first time both "bowel control" and "bladder control" items in the Barthel Index drop to 0 (days) |
| Secondary | Time to Development of Akinetic Mutism | From randomization until the patient meets criteria for akinetic mutism, assessed up to 36 months | Time from randomization to the onset of akinetic mutism, defined as the time at which the patient is independently assessed and jointly confirmed by two investigators to have no spontaneous movements but maintains a sleep-wake cycle (days) |
| Secondary | Changes in MRC-PDRS and Barthel Index Scores | From randomization to each monthly follow-up assessment, assessed every month up to 36 months | Changes in functional assessment scores from randomization to each pre-specified follow-up time point, including MRC-PDRS scores and Barthel Index scores, assessed monthly via telephone follow-up interviews with the patient or caregiver |
| Other | Adverse Events | From randomization until the end of the study, assessed up to 36 months | Incidence, severity, and outcomes of adverse events (AEs) and serious adverse events (SAEs) will be recorded and analyzed, including assessment of their potential relationship to the study treatment. Safety information will be collected through monthly telephone follow-up interviews with the patient or caregiver |
Source ClinicalTrials.gov
Outcomes0
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
None in this release.
Results by group0
Each measurement the trial posted, group by group, in the words and numbers it posted.
None in this release.
Participant flow0
How many started, completed or left each group, period by period.
None in this release.
Adverse events0
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
None in this release.
Adverse event totals0
The totals the trial posted for each group.
None in this release.
Papers2
The papers the trial lists on ClinicalTrials.gov.
Grants0
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
None in this release.
Trial comparisons0
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
None in this release.
Tests0
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
None in this release.
Data dates
The day each source was copied for this release.
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this trial from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/trials/v1/NCT07482085
GET https://conductscience.org/api/trials/v1/NCT07482085/registered